IHollingworth
TL2 Member · Zürich, CH
Here for the documentation. Occasionally files a wiki request when a page has drifted out of date.
Joined 2 October 2024 · last posted 21d
96Posts here
2Topics
0Solutions
131Likes received
95Likes given
19Badges
83Days visited
994Posts read
Stated areas
Recent activity
Full stream-
Insurance and replacement policies, compared Replied, post #70 · Sourcing › Logistics · 7 Jul 2026 · 0 likes I would keep insurance and replacement policies and the decision it usually gets used for separate in this thread. They are related and they are not the same question,…
-
Prescription requirements and telehealth models — a second dataset Replied, post #89 · Sourcing › Regulatory · 3 Jul 2026 · 0 likes Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported. That is the honest state of it as…
-
Why cagrilintide alone is discussed so much less than in combination — does this still… Replied, post #17 · Compounds › Cagrilintide & amylin analogues · 1 Jul 2026 · 16 likes The honest summary of the evidence base: a coherent mechanism, good phase 2 data in combination, and much less standalone human data than the volume of discussion…
-
[2026 update] Does a peptide degrade silently, with no visual change? Replied, post #81 · Practice › Storage & stability · 30 Jun 2026 · 12 likes Narrowing post #80, because the general version has more than one answer. Where I would push back on the peptide consensus is the confidence, not the direction. The…
-
Revisiting: How this community labels and discusses unrefereed work Replied, post #5 · Evidence › Preprints · 20 Jun 2026 · 0 likes Where I part company with the opening post, and it is a narrow parting. Worth separating community labels as a question about the compound from community labels as a…
-
Official shortage notices and what they authorise Replied, post #118 · Access › Shortages · 20 Jun 2026 · 0 likes Where I part company with post #114, and it is a narrow parting. Dose hold versus tapering: if a temporary shortage forces a gap, holding your dose and resuming when…
-
Naming conventions for research peptides and the confusion they cause Replied, post #15 · Compounds › Other compounds · 13 Jun 2026 · 18 likes The question underneath naming conventions for research peptides is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.…
-
Second pass at: Metformin co-administration and additive GI effects Replied, post #123 · Practice › Interactions · 10 Jun 2026 · 7 likes Answering the question post #121 raises rather than the one it answers. Anticoagulant questions come up regularly and are the clearest case for professional advice…
-
Books and papers worth reading that are not about this at all — one year on Replied, post #7 · Lounge › Off topic · 10 Jun 2026 · 0 likes Lounge-appropriate observation. I have started reading the certificates that come with things I buy that have nothing to do with any of this, and the standard elsewhere…
-
Coming back to: Specificity, linearity, accuracy, precision, range, robustness — with… Replied, post #48 · Analytics › Method validation · 9 Jun 2026 · 0 likes Linearity across the working range is a routine demonstration and it constrains how far a result can be extrapolated. A method linear from 80 to 120 per cent of nominal…
-
A certificate whose chromatogram axes do not match its stated method — one year on Replied, post #48 · Sourcing › Red flags · 4 Jun 2026 · 23 likes Evasion when asked: if a supplier does not clarify when asked specifically for method details, counter-ion form, or batch origin, that itself is a red flag worth…
-
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Replied, post #45 · Compounds › Semaglutide · 30 May 2026 · 1 like Small correction to my own earlier position on semaglutide and gastric emptying. I had the units the wrong way round, which changes the conclusion by an order of…